<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721900</url>
  </required_header>
  <id_info>
    <org_study_id>SHX-C301</org_study_id>
    <nct_id>NCT03721900</nct_id>
  </id_info>
  <brief_title>Ketamine for Major Depressive Disorder</brief_title>
  <official_title>A Phase 1 Pharmacokinetics and Pharmacodynamics of Ketamine Transdermal Drug Delivery System in Subjects With Sub-Optimally Responsive Major Depressive Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenox Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenox Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the amount of ketamine in blood over time in subjects
      diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of
      ketamine delivered by transdermal patch.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SHX-C301 is a Phase 1, first in human, single-blind, multi-center clinical study to evaluate
      the pharmacokinetics (PK), safety and antidepressant effects of SHX-001 transdermal patch low
      dose delivered based on prediction and high dose delivered based on the estimation from the
      low dose PK in subjects with MDD and sub-optimally controlled by standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">June 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Each subject will receive one of the following: placebo, 20 mg (low dose), or 40 mg (high dose). All subjects will receive doses in the same order during 3 study periods</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of SHX-001 (Cmax)</measure>
    <time_frame>1 week</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of SHX-001 (Tmax)</measure>
    <time_frame>1 week</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of SHX-001 (T1/2)</measure>
    <time_frame>1 week</time_frame>
    <description>Apparent terminal half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-depressive effects of SHX-001</measure>
    <time_frame>1 week</time_frame>
    <description>Antidepressant effects will be explored by assessing changes in depression assessments (clinician and self-rated)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety objective as measured by Adverse Events (Safety and Tolerability of SHX-001)</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>The safety and tolerability of SHX-001 transdermal patch as an adjunctive therapy to standard of care will be evaluated in subjects with MDD who are sub-optimally responsive to approved antidepressant.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>SHX-001 Active Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine transdermal patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo transdermal patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHX-001 Active high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine transdermal patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHX-001 Active low dose</intervention_name>
    <description>ketamine transdermal patch</description>
    <arm_group_label>SHX-001 Active Low Dose</arm_group_label>
    <other_name>Ketamine transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>transdermal patch</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo transdermal patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHX-001 Active High dose</intervention_name>
    <description>ketamine transdermal patch</description>
    <arm_group_label>SHX-001 Active high dose</arm_group_label>
    <other_name>ketamine transdermal patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present a current depressive episode of at least 8 weeks

          -  Have a body mass index (BMI) of 18-35 kg/m2 (inclusive) at screening

          -  Agree to use adequate methods of contraception during the study (and for X days after
             discharge)

        Exclusion Criteria:

          -  A history of alcohol consumption exceeding 14 drinks/week within the 5 years before
             study entry.

          -  Use of prescription or non-prescription drugs, vitamins, or dietary supplements within
             14 days prior to the first dose of study medication except ongoing stable dose of
             antidepressant.

          -  Treatment with any investigational drug, use of any known CYP3A4
             enzyme-inducing/inhibiting agents (e.g., barbiturates, phenothiazines, cimetidine, St.
             John's Wort) or herbal supplements within 7 days prior to the first dose of study
             medication

          -  A history of drug abuse or dependence within 180 days of screening

          -  A febrile illness within 5 days prior to the first dose of study medication.

          -  A known hypersensitivity to ketamine

          -  A history of use ketamine for Major Depressive Disorder and did not respond to
             ketamine

          -  Recent use of ketamine in any formulation for any indication (within 4 weeks prior to
             screening)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

